TY - JOUR
T1 - Primary pulmonary melanoma
T2 - A report of two cases
AU - Watanabe, Mototsugu
AU - Yamamoto, Hiromasa
AU - Hashida, Shinsuke
AU - Sou, Junichi
AU - Sugimoto, Seiichiro
AU - Toyooka, Shinichi
AU - Miyoshi, Shinichiro
N1 - Publisher Copyright:
© 2015 Watanabe et al.
PY - 2015/9/17
Y1 - 2015/9/17
N2 - Malignant melanoma is a refractory malignancy with a dismal prognosis. It generally arises from the skin in most cases, and cases of primary pulmonary malignant melanoma are rare and often behave aggressively. We have treated two cases of localized primary pulmonary malignant melanoma using surgical resection. Pulmonary malignant melanomas often metastasize to the brain and liver; one of our cases exhibited metastasis to the cecum at about 8months after surgery. Because cutaneous melanomas often carry activating mutations in the BRAF gene (V600E), we performed a BRAF mutational analysis using direct sequencing for both of these tumors arising from the lung. However, no BRAF mutations were detected. We detected a p53 mutation, which was thought to be a potential somatic mutation, in one of the two cases using a sequencing panel targeting 20 lung cancer-related genes. Although we also checked the expression of programmed death ligand 1 (PD-L1) on the surface of the tumor cells by immunohistochemical testing, neither of our two cases expressed PD-L1. Further molecular analyses may uncover the characteristics of primary pulmonary malignant melanomas.
AB - Malignant melanoma is a refractory malignancy with a dismal prognosis. It generally arises from the skin in most cases, and cases of primary pulmonary malignant melanoma are rare and often behave aggressively. We have treated two cases of localized primary pulmonary malignant melanoma using surgical resection. Pulmonary malignant melanomas often metastasize to the brain and liver; one of our cases exhibited metastasis to the cecum at about 8months after surgery. Because cutaneous melanomas often carry activating mutations in the BRAF gene (V600E), we performed a BRAF mutational analysis using direct sequencing for both of these tumors arising from the lung. However, no BRAF mutations were detected. We detected a p53 mutation, which was thought to be a potential somatic mutation, in one of the two cases using a sequencing panel targeting 20 lung cancer-related genes. Although we also checked the expression of programmed death ligand 1 (PD-L1) on the surface of the tumor cells by immunohistochemical testing, neither of our two cases expressed PD-L1. Further molecular analyses may uncover the characteristics of primary pulmonary malignant melanomas.
KW - Primary pulmonary malignant melanoma
KW - Surgical resection
KW - Target sequencing
UR - http://www.scopus.com/inward/record.url?scp=84941614992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941614992&partnerID=8YFLogxK
U2 - 10.1186/s12957-015-0695-2
DO - 10.1186/s12957-015-0695-2
M3 - Article
C2 - 26376781
AN - SCOPUS:84941614992
VL - 13
JO - World Journal of Surgical Oncology
JF - World Journal of Surgical Oncology
SN - 1477-7819
IS - 1
M1 - 274
ER -